A randomized phase II trial of adjuvant trastuzumab emtansine (T-DM1) followed by subcutaneous trastuzumab versus paclitaxel in combination with subcutaneous trastuzumab for Stage I HER2-positive breast cancer (ATEMPT 2.0)

Go Back to All Clinical Trials

A randomized phase II trial of adjuvant trastuzumab emtansine (T-DM1) followed by subcutaneous trastuzumab versus paclitaxel in combination with subcutaneous trastuzumab for Stage I HER2-positive breast cancer (ATEMPT 2.0)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Stage I Her2-positive Breast Cancer
Age: Between 18 years - 100 years
Gender: Male or Female

Other Inclusion Criteria:

1) Patients must have HER2-positive Stage I breast cancer. 2) Patients must have node-negative (N0) or micrometastases (N1mic) breast cancer. 3) Study requires submission of tumor blocks or slides in order to perform biomarker analyses.

You may not be eligible for this study if the following are true:

1) Pregnant women. 2) Nursing women. 3) History of prior chemotherapy in the past 5 years.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies